TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25798215

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplements (1.5 g)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 25798374

Group type: EXPERIMENTAL
Intervention: 16-week group-based intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 68
Study: 25798999

Group type: EXPERIMENTAL
Intervention: (11)C-MRB PET-CT imaging under room temperature (RT) conditions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: (11)C-MRB PET-CT imaging under cold-stimulated conditions
Number of subjects: 10

Group type: COMPARATOR
Intervention: (18)F-FDG PET-CT imaging
Number of subjects: 10
Study: 25800136

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome group (MetS)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Control group (no MetS)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Baseline glomerular filtration rate < 30 mL/min
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Multivessel intervention
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 599
Study: 25800893

Group type: EXPERIMENTAL
Intervention: Minimal residual disease levels <1% on day 19
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Minimal residual disease levels ≥1% on day 19
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Negative minimal residual disease (<0.01%) on day 46 after ≥1% on day 19
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Persistent minimal residual disease on day 46 for standard-risk patients
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Decreasing minimal residual disease levels between end of induction and week 7 of maintenance therapy
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Minimal residual disease re-emergence
Number of subjects: 498
Study: 25801562

Group type: EXPERIMENTAL
Intervention: Triple therapy including telaprevir
Number of subjects: 27

Group type: COMPARATOR
Intervention: After telaprevir withdrawal
Number of subjects: 27

Group type: COMPARATOR
Intervention: PegIFN-α plus ribavirin
Number of subjects: 27
Study: 25801567

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate 300 mg once daily
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: ABCC4 4131 TG or GG genotype
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low body weight, low eGFR, concomitant use of ritonavir-boosted protease inhibitors
Number of subjects: 150
Study: 25801692

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (T&A)
Number of subjects: 100
Study: 25801710

Group type: EXPERIMENTAL
Intervention: Vasodilator stress cardiac MRI
Number of subjects: 139

Group type: COMPARATOR
Intervention: Asymptomatic reference subjects
Number of subjects: 139
Study: 25802238

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 61
Study: 25802729

Group type: EXPERIMENTAL
Intervention: 100 mg canagliflozin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg canagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (diet/exercise alone or diet/exercise plus oral antihyperglycemic drug)
Number of subjects: 0
Study: 25802843

Group type: EXPERIMENTAL
Intervention: Metabolomic profiling using umbilical cord blood samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardised multicentre recruitment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimally invasive biospecimen collection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pristine biobanking and phenotyping
Number of subjects: 0
Study: 25802932

Group type: EXPERIMENTAL
Intervention: Nimotuzumab (200 mg/m² weekly for 4 weeks, then concurrent with gemcitabine (800 mg/m²) or cisplatin (50 mg/m²) for 18 weeks, then maintenance every 2 weeks)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Concurrent phase with chemotherapy (gemcitabine or cisplatin)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nimotuzumab (single agent during induction and maintenance phases)
Number of subjects: 17
Study: 25803093

Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg + Rifampin 600 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bosutinib alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bosutinib + Rifampin
Number of subjects: 24
Study: 25803140

Group type: EXPERIMENTAL
Intervention: Exaggerated HPV subjects (n=33) ascended to 4559m, 4 (13%) developed HAPE during the 48h stay.
Number of subjects: 421

Group type: COMPARATOR
Intervention: Control subjects (n=unknown)
Number of subjects: 421
Study: 25803226

Group type: EXPERIMENTAL
Intervention: Mobile telehealth (MTH) intervention
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 86
Study: 25803243

Group type: EXPERIMENTAL
Intervention: Bronchoscopy with bronchoalveolar lavage (BAL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bronchoscopy with protected-specimen brush
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Comparison of microbiota from spatially separated intrapulmonary sites
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intrasubject variation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Right upper lobe microbiota
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Community richness
Number of subjects: 15
Study: 25803268

Group type: EXPERIMENTAL
Intervention: Histrelin subcutaneous implant
Number of subjects: 36
Study: 25804349

Group type: EXPERIMENTAL
Intervention: Right ventricular pacing (%RVP)
Number of subjects: 1395
Study: 25804569

Group type: EXPERIMENTAL
Intervention: Continuous electrocardiographic monitoring of heart rate (HR) during the first 72 hours after admission.
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of HR during the first 12 hours after admission.
Number of subjects: 702
Study: 25804941

Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 20

Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 20

Group type: COMPARATOR
Intervention: G-CSF with/without chemotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: G-CSF plus plerixafor
Number of subjects: 20

Group type: COMPARATOR
Intervention: G-CSF without plerixafor
Number of subjects: 20
Study: 25805158

Group type: EXPERIMENTAL
Intervention: Use of bleeding avoidance strategies (bivalirudin, radial approach, vascular closure devices)
Number of subjects: 10937

Group type: EXPERIMENTAL
Intervention: Bleeding rates within intervention sites
Number of subjects: 10937

Group type: EXPERIMENTAL
Intervention: Variability in use of bleeding avoidance strategies
Number of subjects: 10937
Study: 25805361

Group type: EXPERIMENTAL
Intervention: Adeno-tonsillectomy (AT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 144
Study: 25806103

Group type: EXPERIMENTAL
Intervention: Energy-restricted ketogenic diet (ERKD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ketogenic diet (KD)
Number of subjects: 32
Study: 25806231

Group type: EXPERIMENTAL
Intervention: Customized chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin/gemcitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin/docetaxel or docetaxel alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-customized cisplatin/docetaxel
Number of subjects: 0
Study: 25806291

Group type: EXPERIMENTAL
Intervention: Erlotinib treatment with low/intermediate ROR1 levels
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Erlotinib treatment with high ROR1 levels
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment with low/intermediate ROR1 levels
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment with high ROR1 levels
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Erlotinib treatment with T790M mutation and low/intermediate ROR1 levels
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Erlotinib treatment with T790M mutation and high ROR1 levels
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment with T790M mutation and low/intermediate ROR1 levels
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment with T790M mutation and high ROR1 levels
Number of subjects: 45
Study: 25806824

Group type: EXPERIMENTAL
Intervention: Aerobic fitness (measured by VO2 peak)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Micronutrient status adjustment
Number of subjects: 273
Study: 25807199

Group type: EXPERIMENTAL
Intervention: FMSA
Number of subjects: 25

Group type: COMPARATOR
Intervention: CellSearch®
Number of subjects: 25
Study: 25807932

Group type: EXPERIMENTAL
Intervention: Lisinopril (0.1 mg/kg/day)
Number of subjects: 22
Study: 25809054

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessments, clinical and diagnostic information, biological and molecular markers.
Number of subjects: 3479

Group type: EXPERIMENTAL
Intervention: Functional and clinical parameters recorded before, during hospital admission and at discharge.
Number of subjects: 3479
Study: 25809354

Group type: EXPERIMENTAL
Intervention: EndoAnchors
Number of subjects: 208
Study: 25809731

Group type: EXPERIMENTAL
Intervention: NVP-AUY922 monotherapy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: NVP-AUY922 plus bortezomib
Number of subjects: 29
Study: 25809824

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (25 mg/m² every 3 weeks plus daily prednisolone)
Number of subjects: 44
Study: 25810005

Group type: EXPERIMENTAL
Intervention: Physician-assessed FN risk
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Model-predicted FN risk
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: G-CSF primary prophylaxis orders
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: G-CSF orders relative to physician's FN risk intervention threshold
Number of subjects: 944
Study: 25811755

Group type: EXPERIMENTAL
Intervention: Worse CSHQ score (Children's Sleep Habits Questionnaire)
Number of subjects: 1970

Group type: EXPERIMENTAL
Intervention: More night-time sleep
Number of subjects: 1970

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 1970

Group type: EXPERIMENTAL
Intervention: Time outdoors
Number of subjects: 1970

Group type: EXPERIMENTAL
Intervention: Total sleep duration (night + midday)
Number of subjects: 1970
Study: 25812009

Group type: EXPERIMENTAL
Intervention: 5 mg glipizide × 1
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: 500 mg metformin × 2 days
Number of subjects: 668
Study: 25812438

Group type: EXPERIMENTAL
Intervention: 99mTc-PulmoBind (5 mCi)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 99mTc-PulmoBind (10 mCi)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 99mTc-PulmoBind (15 mCi)
Number of subjects: 20
Study: 25812924

Group type: EXPERIMENTAL
Intervention: Subretinal visual implant (Alpha IMS)
Number of subjects: 29
Study: 25813372

Group type: EXPERIMENTAL
Intervention: HeartWare Ventricular Assist Device (HVAD)
Number of subjects: 332
Study: 25815033

Group type: EXPERIMENTAL
Intervention: WATSU (WaterShiatsu)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Passive control (no treatment)
Number of subjects: 9
Study: 25815190

Group type: EXPERIMENTAL
Intervention: Hand in Hand intervention (4-8 couple sessions with a psychologist in addition to usual care)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 199
Study: 25816051

Group type: EXPERIMENTAL
Intervention: Intraportal islet cell transplantation with 2-5 × 10(6) β-cells per kilogram of body weight
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Undetectable plasma GAD65
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intermediate levels of plasma GAD65
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Diabetic nude rat recipients without hyperglycemic correction
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cultured human β-cells after acute insult
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Plasma GAD65 detection
Number of subjects: 56
Study: 25818272

Group type: EXPERIMENTAL
Intervention: Standardised ventilator settings (SVS) at 24 hours
Number of subjects: 478

Group type: COMPARATOR
Intervention: Baseline PaO₂/FiO₂
Number of subjects: 478

Group type: COMPARATOR
Intervention: Usual care at 24 hours without SVS
Number of subjects: 478
Study: 25818754

Group type: EXPERIMENTAL
Intervention: 4 contrast agents used in Coronary CT angiography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 25819287

Group type: EXPERIMENTAL
Intervention: High Dose Rate Brachytherapy (HDR-BT)
Number of subjects: 0
Study: 25819643

Group type: EXPERIMENTAL
Intervention: Tremelimumab 10 mg/kg once every 4 weeks for six doses, then every 12 weeks until disease progression, unacceptable toxic effects, or refusal to continue treatment.
Number of subjects: 29
Study: 25819852

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care anticoagulant treatment
Number of subjects: 0
Study: 25820067

Group type: EXPERIMENTAL
Intervention: DNA vaccines (3 vaccinations)
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: DNA vaccines (increased DNA dosage)
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Lower body mass index
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: DNA vaccines
Number of subjects: 1218
Study: 25820680

Group type: EXPERIMENTAL
Intervention: CardShock risk Score including variables such as ACS aetiology, age, previous myocardial infarction, prior coronary artery bypass, confusion, low LVEF, and blood lactate levels.
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Patients with ACS aetiology.
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Overall in-hospital mortality rate.
Number of subjects: 219
Study: 25821795

Group type: EXPERIMENTAL
Intervention: MIF173*C genotype carriers
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: CHD patients
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Patients with unstable angina pectoris (UAP)
Number of subjects: 256

Group type: COMPARATOR
Intervention: C genotype
Number of subjects: 256

Group type: COMPARATOR
Intervention: 173*CC genotype
Number of subjects: 256
Study: 25821963

Group type: EXPERIMENTAL
Intervention: TDF + 3TC + LPV/r
Number of subjects: 80
Study: 25822102

Group type: EXPERIMENTAL
Intervention: Germline ARMC5 genetic alterations identified in 20 unrelated and 2 related individuals (39.3% prevalence).
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ARMC5 sequence changes predicted to be damaging by in silico analysis.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Affected patients carrying a variant predicted to be damaging were all African Americans.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Screening for ARMC5 sequence variants in cohorts of primary aldosteronism and metabolic syndrome, particularly in African Americans.
Number of subjects: 56
Study: 25822672

Group type: EXPERIMENTAL
Intervention: MRI assessment with 'safe' mrLRP
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: MRI assessment with 'unsafe' mrLRP
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Posttreatment MRI reassessment with 'safe' ymrLRP
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Posttreatment MRI reassessment with 'unsafe' ymrLRP
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Independent MRI assessed risk factors (EMVI)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Independent MRI assessed risk factors (tumors < 4.0 cm from anal verge)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Independent MRI assessed risk factors (anterior tumors)
Number of subjects: 279
Study: 25822727

Group type: EXPERIMENTAL
Intervention: Unicirc instrument with topical lidocaine/prilocaine anesthetic
Number of subjects: 110
Study: 25822820

Group type: EXPERIMENTAL
Intervention: Agalsidase alfa (agalα; 0.2 mg/kg every other week)
Number of subjects: 100
Study: 25823600

Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Oral Immunotherapy (No OIT)
Number of subjects: 0
Study: 25823737

Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating T cells selected for HPV E6 and E7 reactivity (HPV-TILs) infused after lymphocyte-depleting chemotherapy and followed by aldesleukin administration.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HPV-TILs infusion product
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Frequency of HPV-reactive T cells in peripheral blood 1 month after treatment
Number of subjects: 9
Study: 25823919

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone buccal film (BBN)
Number of subjects: 249
Study: 25824111

Group type: EXPERIMENTAL
Intervention: Bortezomib-based treatment regimens (VDD: bortezomib, liposomal doxorubicin, dexamethasone; RVD: lenalidomide, bortezomib, dexamethasone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib-based treatment regimens
Number of subjects: 0
Study: 25824215

Group type: EXPERIMENTAL
Intervention: Rifapentine 10 mg/kg twice daily for 14 days
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rifapentine 20 mg/kg once daily for 14 days
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rifapentine 15 mg/kg once daily with a high-fat breakfast
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rifapentine divided dosing (e.g., 1,500 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Rifapentine with a low-fat breakfast
Number of subjects: 44
Study: 25824314

Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy (RT) without lytic agent
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PCDT)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: PCDT and catheter-directed thrombolysis (CDT)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: RT in combination with CDT
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: All treatment approaches
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Rheolytic PCDT treatment
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: AngioJet procedure
Number of subjects: 329
Study: 25824400

Group type: EXPERIMENTAL
Intervention: Homeopathic complex remedy (Pascallerg®)
Number of subjects: 123
Study: 25824474

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 2022
Study: 25824692

Group type: EXPERIMENTAL
Intervention: HCT conditioning regimen with cyclophosphamide (CY), total body irradiation (TBI), antithymocyte globulin (ATG), and fludarabine (FLU)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: HCT conditioning regimen with TBI 300 cGy, CY, FLU, and ATG
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: HCT conditioning regimen
Number of subjects: 130
Study: 25825008

Group type: EXPERIMENTAL
Intervention: Thrombus-containing lesions (TCLs) present
Number of subjects: 4449

Group type: COMPARATOR
Intervention: No thrombus-containing lesions (TCLs)
Number of subjects: 4449
Study: 25825044

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacemaker
Number of subjects: 253

Group type: COMPARATOR
Intervention: Carotid sinus massage (CSM)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Tilt testing (TT)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Implantable loop recorder (ILR)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Non-diagnostic tests with ILR
Number of subjects: 253
Study: 25825476

Group type: EXPERIMENTAL
Intervention: Afatinib (20 mg/d) and trastuzumab (6 mg/kg/3 weeks) for 6 weeks, followed by paclitaxel (80 mg/m2/1 week), trastuzumab, and afatinib for 12 weeks, followed by epirubicin (90 mg/m2/3 weeks), cyclophosphamide (600 mg/m2/3 weeks), and trastuzumab for 12 weeks
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Afatinib and trastuzumab
Number of subjects: 65
Study: 25825625

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) administered stroke symptom questionnaire (QVSFS)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Assessment by two trained neurologists
Number of subjects: 322
Study: 25825629

Group type: EXPERIMENTAL
Intervention: Asymptomatic ICAD positive individuals
Number of subjects: 200

Group type: COMPARATOR
Intervention: Asymptomatic ICAD negative individuals
Number of subjects: 200
Study: 25826274

Group type: EXPERIMENTAL
Intervention: Cholangioscopy-guided sampling
Number of subjects: 47
Study: 25827180

Group type: EXPERIMENTAL
Intervention: FLASH-PD frames
Number of subjects: 20

Group type: COMPARATOR
Intervention: SSFP-PD images
Number of subjects: 20
Study: 25827220

Group type: EXPERIMENTAL
Intervention: 25 minute post gadolinium T1 time
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Native T1 time
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Partition coefficient
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: 2013 AHA/ASCVD risk score
Number of subjects: 1208
Study: 25827757

Group type: EXPERIMENTAL
Intervention: Group 4 (AHI: 5-15/h and >30 % of TST with IFL)
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: More than 30 % of TST with IFL
Number of subjects: 754
Study: 25827820

Group type: EXPERIMENTAL
Intervention: MK-2206 (60 mg every other day)
Number of subjects: 70
Study: 25827941

Group type: EXPERIMENTAL
Intervention: Dalteparin (subcutaneous) for 12 months
Number of subjects: 334
Study: 25828318

Group type: EXPERIMENTAL
Intervention: Risk scores
Number of subjects: 0
Study: 25828395

Group type: EXPERIMENTAL
Intervention: Age/Sex/Gene Expression Score (ASGES) testing
Number of subjects: 320

Group type: COMPARATOR
Intervention: Low ASGES (ASGES ≤15)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Elevated ASGES (ASGES >15)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Overall follow-up major adverse cardiac event/revascularization rate
Number of subjects: 320
Study: 25829395

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg kg(-1)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (normal renal function)
Number of subjects: 67
Study: 25829400

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1,000 mg/day
Number of subjects: 2265
Study: 25829804

Group type: EXPERIMENTAL
Intervention: Abcertin® administered at the same dose as imiglucerase (30 to 55 U/kg every other week) for 24 weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Abcertin® continued for another 24 weeks in three patients
Number of subjects: 5
Study: 25830171

Group type: COMPARATOR
Intervention: Emergency Department patients
Number of subjects: 0